Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity

Leukemia Research

Volumn 32, Issue 8, 2008, Pages 1321-1322

  Chevallier, Patrice ^a   Touzeau, Cyril ^a   Ayari, Sameh ^a   Guillaume, Thierry ^a   Harousseau, Jean Luc ^a   Delaunay, Jacques ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; HUMAN; HYPERBILIRUBINEMIA; LOW DRUG DOSE; PHENOTYPE; PRIORITY JOURNAL;

AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; FEASIBILITY STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; REMISSION INDUCTION;

EID: 42949122653     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.09.009     Document Type: Article

References (8)

1. Larson R.A., Sievers E.L., Stadtmauer E.A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104 (2005) 1442-1452
2. Tsimbaridou A., Estey E., Cortes J., et al. Gemtuzumab, Fludarabine, Cytarabine and Cyclosporine in patients with newly diagnosed acute myelogenous leukaemia or high-risk myelodysplastic syndromes. Cancer 97 (2003) 1481-1487
3. Nabhan C., Rundhaugen L.M., Riley M.B., et al. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukaemia age 65 or older. Leuk Res 29 (2005) 53-57
4. Tsimbaridou A., Cortes J., Thomas D., et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 27 (2003) 893-897
5. Mineur P., Lejeune C., Hennaux V., et al. Antibody-targeted chemotherapy of relapsed AML. Br J Haematol 121 (2003) 195-196
6. Zwaan C.M., Reinhardt D., Corbacioglu S., et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukaemia treated on compassionate-use basis. Blood 101 (2003) 3868-3871
7. Chevallier P., Roland V., Mahe B., et al. Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukaemia. Leuk Res 29 (2005) 1003-1007
8. Burnett A.K., Kell W.J., Goldstone A.H., et al. The addition of Gemtuzumab Ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. Blood 108 (2006) 8a [abstract 13]